Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (311-320 of 426) with videos related to

Pageof 43
Sort By:
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Pageof 43

Showing results (311-320 of 426) with videos related to

Sort By:
Pageof 43
European Urology|March 8, 2021
CD38 in Advanced Prostate CancersChristina Guo, Mateus Crespo, Bora Gurel, et al.
Investigational New Drugs|March 3, 2026
Phase I multi-center clinical and biomarker study of the dual-action androgen receptor inhibitor ONCT-534Matthew R Chrostek, James Robinson, Rajesh Krishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.
European Urology Oncology|October 31, 2025
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to TherapyKarim Fizazi, Johann S de Bono, A Douglas Laird, et al.
Clinical Genitourinary Cancer|June 3, 2017
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden HospitalDiletta Bianchini, David Lorente, Pasquale Rescigno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2021
Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB DependenciesYi Liang, Sujeeve Jeganathan, Stefano Marastoni, et al.
European Urology|July 3, 2014
Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trialGerhardt Attard, Matthew R Sydes, Malcolm D Mason, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin LymphomaAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Cancer|June 23, 2022
Clinical activity of CC-90011, an oral, potent, and reversible LSD1 inhibitor, in advanced malignanciesAntoine Hollebecque, Stefania Salvagni, Ruth Plummer, et al.
Pageof 43